1. Home
  2. WEAV vs CABA Comparison

WEAV vs CABA Comparison

Compare WEAV & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weave Communications Inc.

WEAV

Weave Communications Inc.

HOLD

Current Price

$7.28

Market Cap

413.7M

Sector

Technology

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.91

Market Cap

495.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEAV
CABA
Founded
2011
2017
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
413.7M
495.7M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
WEAV
CABA
Price
$7.28
$2.91
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
$11.00
$14.50
AVG Volume (30 Days)
1.2M
3.0M
Earning Date
04-30-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
7.50
10.26
EPS
N/A
N/A
Revenue
$239,024,000.00
N/A
Revenue This Year
$17.20
N/A
Revenue Next Year
$13.74
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.99
N/A
52 Week Low
$4.24
$1.41
52 Week High
$8.11
$4.23

Technical Indicators

Market Signals
Indicator
WEAV
CABA
Relative Strength Index (RSI) 63.11 53.92
Support Level $6.71 $2.67
Resistance Level $7.35 $3.34
Average True Range (ATR) 0.32 0.14
MACD 0.01 0.03
Stochastic Oscillator 99.06 72.84

Price Performance

Historical Comparison
WEAV
CABA

About WEAV Weave Communications Inc.

Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and generates revenue mainly from subscriptions.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Share on Social Networks: